Potential drug interactions of oral hypoglycemic drugs that increase the risk of hypoglycemia
- 作者: Pereverzev A.P1,2, Ostroumova O.D.1,2, Tkacheva O.N1,2
-
隶属关系:
- Pirogov Russian National Research Medical University
- Russian Clinical and Research Center of Gerontology
- 期: 卷 26, 编号 4 (2019)
- 页面: 96-99
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/297976
- DOI: https://doi.org/10.18565/pharmateca.2019.4.96-99
- ID: 297976
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Type 2 diabetes mellitus (DM2) is a metabolic disease that develops as a result of insulin secretion dysfunction or reduced tissue sensitivity to insulin action (insulin resistance). DM2 patients often suffer not only from the symptoms of elevated blood glucose levels, but also from the manifestations and complications of comorbidities that dictate the need for prescribing drug therapy. As a result, diabetic patients have a high risk of polypragmasy, which can cause a serious complication - hypoglycemia. The article provides a brief overview of some pharmacokinetic and pharmacodynamic interactions of glucose-lowering drugs, including with food and biologically active supplements.
全文:
作者简介
A. Pereverzev
Pirogov Russian National Research Medical University; Russian Clinical and Research Center of Gerontology
Olga Ostroumova
Pirogov Russian National Research Medical University; Russian Clinical and Research Center of Gerontology
Email: ostroumova.olga@mail.ru
Ostroumova, MD, Professor, member of the Russian Association of Gerontologists and Geriatricians (RAGG), Pirogov Russian National Research Medical University
O. Tkacheva
Pirogov Russian National Research Medical University; Russian Clinical and Research Center of Gerontology
参考
- Дедов И.И, Шестакова М.В. Сахарный диабет. Диагностика. Лечение. Профилактика. М.:МИА, 2011. 808с.
- May M., Schindler. C. Clinicaiiy and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69-83.
- Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. Сахарный диабет. 2017;20(1S):1-112. doi: 10.14341/DM20171S8.
- Scheen A.J. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359-71.
- Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40 (7 Suppl.):S3-8. doi: 10.1007/s002800051053.
- Kerb R., Hoffmeyer S., Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001;2(1):51-64. doi: 10.1517/14622416.2.1.51.
- Государственный реестр лекарственных средств. URL: http://www.grls.rosminzdrav.ru (дата обращения: 23.02.2019).
- Holstein A., Beil W., Kovacs P CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 2012;8(12):1549-63.
- Franconi F., Brunelleschi S., Steardo L., Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81-95.
- Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41(5):329-42.
- База данных информации о ЛС «Drugbank». URL: https://www.drugbank.ca (дата обращения: 23.02.2019).
- База данных информации о ЛС «Drugs.com». URL https://www.drugs.com (дата обращения: 23.02.2019).
- Bennett W.L., Maruthur N.M., Singh S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9): 602-13.
- Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15(6):540-59.
补充文件
